ACRS:NSD-Aclaris Therapeutics Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 14.73

Change

+0.90 (+6.51)%

Market Cap

USD 0.92B

Volume

0.43M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ACRS Stock Forecast & Price:
Based on the Aclaris Therapeutics Inc stock forecasts from 0 analysts, the average analyst target price for Aclaris Therapeutics Inc is not available over the next 12 months. Aclaris Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aclaris Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Aclaris Therapeutics Inc’s stock price was USD 14.73. Aclaris Therapeutics Inc’s stock price has changed by +4.77% over the past week, -0.20% over the past month and -13.71% over the last year.

About Aclaris Therapeutics Inc (ACRS:NSD)

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in iden ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-05 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
IDXX IDEXX Laboratories Inc

+8.43 (+2.35%)

USD30.11B 41.15 30.01
ILMN Illumina Inc

+1.98 (+1.04%)

USD30.01B 40.13 26.38
ICLR ICON PLC

+3.76 (+1.77%)

USD17.34B 119.50 29.02
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
SYNH INC Research Holdings Inc

+1.63 (+2.28%)

USD7.34B 30.98 16.69
EXAS EXACT Sciences Corporation

+3.27 (+7.95%)

USD7.24B N/A -15.87
MEDP Medpace Holdings Inc

+7.10 (+4.75%)

USD4.80B 27.96 20.45
GH Guardant Health Inc

+3.78 (+8.66%)

USD4.45B N/A -13.23
LNTH Lantheus Holdings Inc

+1.23 (+1.94%)

USD4.36B 2,335.00 211.49
NTRA Natera Inc

+1.86 (+5.04%)

USD3.56B N/A -6.25

ETFs Containing ACRS

Symbol Name Weight Mer Price(Change) Market Cap
DWAS Invesco DWA SmallCap Mome.. 0.00 % 0.60 %

-1.21 (-1.78%)

USD0.37B

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.31% 95% A 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.31% 95% A 89% B+
Trailing 12 Months  
Capital Gain -12.74% 91% A- 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.74% 91% A- 62% D-
Trailing 5 Years  
Capital Gain -46.38% 50% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.38% 50% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 229.55% 93% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 229.55% 93% A 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 588.06% 7% F 2% F
Risk Adjusted Return 39.03% 56% F 70% C-
Market Capitalization 0.92B 59% F 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.11 20% F 16% F
Price / Cash Flow Ratio -17.66 86% B 82% B-
EV/EBITDA -10.23 91% A- 86% B
Management Effectiveness  
Return on Equity -55.32% 34% F 22% F
Return on Invested Capital -73.05% 20% F 14% F
Return on Assets -23.65% 33% F 18% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 9.64 7% F 11% F
Short Percent 5.56% 48% F 33% F
Beta 0.69 82% B- 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.